Outlook’s Wet AMD Candidate Faces Second FDA Rejection
Outlook Therapeutics has received a second rejection from the FDA for its wet age-related macular…
Newswire
A New Dawn for GCA Treatment
In the realm of chronic autoimmune disorders, giant cell arteritis (GCA) has long been a…
Turning Cancer on Its Head
Cancer cells are no longer just enemies, but unwilling partners in their own defeat. This…
FDA’s Bold Move: Pfizer’s EUA Revoked
In a surprising twist, the FDA has pulled the emergency use authorization for Pfizer’s Covid…
Digital Twins: The Future of Obesity Treatment?
With a recent $53 million Series E funding round led by Denmark’s Novo Holdings, Twin…
Navigating Online Pharmacy Risks
The FDA’s BeSafeRx initiative shines a spotlight on the often-overlooked risks associated with purchasing medications…
Disaster-Ready: Are We Prepared?
Picture this: a hurricane approaches, and the clock is ticking. In the chaos, the last…